PRESS RELEASE
Egetis Therapeutics AB
Stockholm, Sweden, March 26, 2021

Dr Thomas Lönngren nominated as new Chairman of the Board at Egetis Therapeutics

Stockholm, Sweden, March 26, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that the nomination committee proposes that the former Head of the European Medicines Agency (EMA), Dr Thomas Lönngren, is appointed Chairman of the Board of Directors of Egetis Therapeutics. He replaces Håkan Åström, who has served as Chairman since 2011. The decision will be taken at the Annual General Meeting on April 29, and a notice will be sent out separately.

Dr Lönngren has extensive experience as a senior executive within the life science community, serving as Deputy General Director of the Swedish Medical Product Agency (MPA) up to 2000 followed by EMA, where he led the agency as Executive Director between 2001 and 2010. At EMA, he oversaw the implementation of several EU regulatory reforms, including the Orphan drug legislation, Pediatrics legislation, revised Pharmacovigilance legislation and Advanced Therapies legislation.

He also has a vast experience as a board member and scientific adviser in the global biotech and medtech industry, with a specific focus on drug regulation, approval, market access, management, strategy and leadership.

Dr Lönngren has a Master of Science degree in social and regulatory pharmacy, University of Uppsala, and a degree in Pharmacy, Pharmaceutical Faculty, University of Uppsala. Dr Lönngren has received a number of Honors and Awards for his contributions in the medicine world and among them holds an Honorary Doctorate from the University of Uppsala, Sweden and is an Honorary Member of the Royal Pharmaceutical Society of Great Britain and an Honorary Fellow of the Royal College of Physicians in Great Britain.

“We are incredibly happy to be able attract such a senior professional and life science executive as Thomas to the company. With our strategic focus on late-stage orphan development, registration and commercialization, we believe that his experience, expertise and networks will significantly benefit the company. The current Chairman Håkan Åström, who has been with the company for ten years, has declined re-election due to personal reasons, and I want to thank Håkan for the tremendous, skilled and invaluable work he has put into the business over this period”, said Kennet Rooth, Chairman of the nomination committee.

“I am very excited to join Egetis Therapeutics in their continued journey to build an orphan focused company. Egetis has a highly competent team and two late-stage assets that look very promising and could reach the market already in a few years time. I look forward to working together with CEO Nicklas Westerholm and his team and the rest of the Board to achieve this goal and further grow and develop the company over the coming years”, said Dr Thomas Lönngren.

For further information, please contact:
Nicklas Westerholm, CEO, Egetis Therapeutics
Tel. +46 (0)73 354 20 62
Email: nicklas.westerholm@egetis.com

This information is information that Egetis Therapeutics AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 2021-03-26, 08:05 CET.

About Egetis Therapeutics

Egetis Therapeutics is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment. The drug candidate Emcitate is developed as the first potential treatment for patients with MCT8 deficiency, a rare disease with high unmet medical need and no available treatment. A Phase IIb clinical trial has been completed with significant and clinically relevant effects. A pivotal Phase IIb/III early intervention study has been initiated in Dec 2020 with the first patient dosed and interim results are expected in 2022. Emcitate holds Orphan Drug Designation in the US and EU and was granted Rare Pediatric Disease Designation by the US FDA in November 2020. The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol poisoning. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase IIb/III study for Aladote has been finalized after completed interactions with FDA, EMA and MHRA. Aladote has been granted Orphan Drug Designation in the US. Results from the PledOx POLAR program in Dec 2020 shows that PledOx did not meet the efficacy endpoint. Based on further evaluation of the results from the POLAR studies, the strategic next steps for PledOx will be determined together with our partner Solasia.

Egetis Therapeutics (STO: EGTX) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see www.egetis.com